Guideline 6.1 – Peri-Transplant Anaemia:
We suggest that anaemia management should be optimal pre-transplant in all people with CKD on the transplant wait-list, to minimise the risk of a post-transplant transfusion. (2B)
Guideline 6.1.1
We suggest that for people with CKD undergoing kidney transplantation, ESA therapy may be continued, after a shared decision with the patient taking account of risks and benefits, until endogenous EPO production is sufficient to maintain Hb concentrations. For HIF-PHI therapy we make no recommendation until further data are available. (2C)
Guideline 6.2 – Blood Transfusion:
We suggest for stable non-bleeding individuals who clinically require a red cell transfusion, use single unit transfusion, where possible. (2B)
Guideline 6.3 – Post-Transplant Anaemia:
We suggest that consideration is given to identify (and correct) reversible transplant-specific causes of anaemia. (2B)
Guideline 6.3.1
We recommend that the treatment guidelines for anaemia in kidney transplant recipients should be similar to those for people with CKD not on dialysis (NDD-CKD). (1B)
Guideline 6.3.2
We suggest for stable non-bleeding individuals who clinically require a red cell transfusion, use single unit transfusion, where possible. (2B)
Guideline 6.3.3
We suggest the use of HIF-PHI therapy in transplant recipients should be as in people with NDD-CKD. (2B)